✦ LIBER ✦

Cytomegalovirus Immunoglobulin Decreases the Risk of Cytomegalovirus Infection but not Disease After Pediatric Lung Transplantation

✍ Scribed by Kavitha Ranganathan; Sarah Worley; Marian G. Michaels; Susana Arrigan; Paul Aurora; Manfred Ballmann; Debra Boyer; Carol Conrad; Irmgard Eichler; Okan Elidemir; Samuel Goldfarb; George B. Mallory Jr; Peter J. Mogayzel; Daiva Parakininkas; Melinda Solomon; Gary Visner; Stuart C. Sweet; Albert Faro; Lara Danziger-Isakov

Book ID: 116521899
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 329 KB
Volume: 28
Category: Article
ISSN: 1557-3117
DOI: 10.1016/j.healun.2009.04.032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

502: CMVIG Decreases the Risk of Cytomeg

502: CMVIG Decreases the Risk of Cytomegalovirus Infection but Not Disease after Pediatric Lung Transplantation

✍ L. Danziger-Isakov; M.G. Michaels; K. Ranganathan; S. Worley; S. Arrigain; P. Au 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Cytomegalovirus infection does not incre

Cytomegalovirus infection does not increase the risk of vanishing bile duct syndrome after liver transplantation

✍ A. P. van den Berg; I. J. Klompmaker; B. G. Hepkema; A. S. H. Gouw; E. B. Haagsm 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 212 KB

244 -455 G/A fibrinogen promoter polymor

244 -455 G/A fibrinogen promoter polymorphism and Cytomegalovirus infection modulate fibrinogen levels but not the risk of premature coronary heart disease

📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 115 KB

Retrospective review of the incidence of

Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: Comparison of prophylactic oral ganciclovir and oral valganciclovir

✍ Ashley N. Bedel; Trina S. Hemmelgarn; Rohit Kohli 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 747 KB

Cytomegalovirus (CMV) is the most common viral infection after solid organ transplantation (SOT). Safe and effective prophylactic regimens that decrease its incidence after SOT are essential for long-term graft survival. Although valganciclovir is not Food and Drug Administration-approved for CMV pr